Genentech Plans Lucentis Launch Within 72 Hours Of Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech intends for its pending neovascular wet age-related macular degeneration product Lucentis (ranibizumab) to be available within three days of its approval